Expertise in
12
conditions

Dr. Stephen H. Bush

Oncology
CAMC Cancer Center
3415 Maccorkle Ave SE, 
Charleston, WV 
Accepting New Patients
Expertise in
12
conditions
CAMC Cancer Center
3415 Maccorkle Ave SE, 
Charleston, WV 

Overview

Stephen Bush is an Oncologist practicing medicine in Charleston, West Virginia.

Dr. Bush is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Malignant Mixed Mullerian Tumor, and Salpingo-Oophorectomy.

He is actively involved in clinical research, co-authoring 27 peer reviewed articles and participating in 6 clinical trials. Dr. Bush is currently accepting new patients.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in FL

Hospital Affiliations

Charleston Area Medical Center
Camc Greenbrier Valley Medical Center, Inc
Camc Plateau Medical Center, Inc
Thomas Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Peak Health
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

CAMC Cancer Center
3415 Maccorkle Ave SE, Charleston, WV 25304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2024
Intervention Type: Diagnostic test, Drug
Study Drug: Standard Chemotherapy
Study Phase: Phase 3
View 5 Less Clinical Trials

26 Total Publications

Hysterectomy and Myomectomy versus Uterine Artery Embolization for Symptomatic Fibroids and Adenomyosis: National and Regional Trends and Adverse Events in 70,000 Patients.
Hysterectomy and Myomectomy versus Uterine Artery Embolization for Symptomatic Fibroids and Adenomyosis: National and Regional Trends and Adverse Events in 70,000 Patients.
Journal: Journal of vascular and interventional radiology : JVIR
Published: October 23, 2024
Similar Doctors
Expertise in
52
conditions
Expertise in
52
conditions
Referral may be required

CAMC Cancer Center

3415 Maccorkle Ave SE, 
Charleston, WV 
 (0.1 miles away)
304-388-8380
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ahmed Khalid is an Oncologist practicing medicine in Charleston, West Virginia. Dr. Khalid is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Anal Cancer, Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Khalid is currently accepting new patients.

Expertise in
39
conditions
Expertise in
39
conditions
Referral may be required

CAMC Cancer Center

3415 Maccorkle Ave SE, 
Charleston, WV 
 (0.1 miles away)
304-388-8380
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Justin Cohen is an Oncologist practicing medicine in Charleston, West Virginia. Dr. Cohen is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Posterior Fossa Tumor, and Bone Marrow Aspiration. Dr. Cohen is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

CAMC Cancer Center

3415 Maccorkle Ave SE, 
Charleston, WV 
 (0.1 miles away)
304-388-8380
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adesola Awomolo is an Oncologist practicing medicine in Charleston, West Virginia. Dr. Awomolo is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Inflammatory Breast Cancer, Breast Cancer, Paget Disease of the Breast, and EGFR Positive Lung Cancer. Dr. Awomolo is currently accepting new patients.

Frequently Asked Questions about Dr. Stephen H. Bush

How do I make an appointment with Dr. Stephen H. Bush?

You can book an appointment with Dr. Stephen H. Bush by calling their office at 304-388-8380. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Stephen H. Bush a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Stephen H. Bush is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Stephen H. Bush specialize in?

While Dr. Stephen H. Bush is a Oncology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Cervical Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Stephen H. Bush participate in research or clinical trials?

Yes. Dr. Stephen H. Bush has published 26 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Stephen H. Bush's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Stephen H. Bush accept my insurance?

Dr. Stephen H. Bush accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 304-388-8380 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bush's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile